Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
Histopathologic review of suspected disease progression in patients with recurrent glioblastoma (GBM) receiving nivolumab +/- ipilimumab: CheckMate 143. Sahebjam, S., Ramkissoon, S., Baehring, J. M., Mulholland, P., Grauer, O. M., Cloughesy, T., Reardon, D. A., Lim, M., Zwirtes, R. F., Latek, R., Strauss, L. C., Ligon, K. L. AMER SOC CLINICAL ONCOLOGY. 2017
View details for DOI 10.1200/JCO.2017.35.15_suppl.2001
View details for Web of Science ID 000411895703171